Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
MEDCL Stock Chart & Stats
€20.34
-€0.24(-1.39%)
At close: 4:00 PM EST
€20.34
-€0.24(-1.39%)
Day’s Range― - ―
52-Week Range€12.00 - €39.68
Previous CloseN/A
Volume18.50K
Average Volume (3M)179.66K
Market Cap
€730.23M
Enterprise Value€720.88M
Total Cash (Recent Filing)€53.50M
Total Debt (Recent Filing)€58.27M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Jun 16, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,905,018
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)-25.60
Price to Sales (P/S)16.41
P/FCF Ratio23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.60Price Target Upside79.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)€33.46M
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformMedinCell's BEPO polymer depot technology is a durable competitive asset: it enables multi-month delivery across therapeutic areas, supports licensing and royalties, and creates technical barriers to entry. Platform breadth sustains long-term partner interest and repeat deal flow.
Partner Commercial TractionRobust UZEDY sales under Teva validate MedinCell's technology in market, creating ongoing royalty streams and recurring revenue potential. Strong partner execution reduces commercialization risk and supports durable top-line growth and credibility with future collaborators.
Cash RunwayA ~EUR53m cash position gives multi-year runway, reducing near-term financing pressure and allowing sustained R&D and regulatory work. This buffer supports milestone-driven value capture and gives management time to achieve approvals or partner payments.
Bears Say
Balance Sheet LeverageNegative equity and a large negative debt-to-equity ratio indicate structural leverage and solvency risk. This limits strategic flexibility, raises refinancing or covenant concerns, and increases the likelihood of dilutive or costly funding if partners or milestones slip.
Persistent UnprofitabilityDeep negative margins signal structural unprofitability driven by R&D and operating costs. Unless offset by scaling royalties or sustained partner payments, this profile requires ongoing funding and increases financing or dilution risk over the multi-quarter horizon.
Partner & Milestone ConcentrationMedinCell's business model relies on partner-driven development, approvals and launches. This concentrates execution and cashflow risk: regulatory delays or partner underperformance can defer milestones, compress royalty timing and materially affect multi-year revenue visibility.
MedinCell SA News
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €12.00 and its highest was €39.68 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €730.23M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Jun 16, 2026 which is in 92 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Dec 09, 2025. The company reported -€0.49 earnings per share for the quarter, missing the consensus estimate of -€0.18 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is 0.02.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,905,018 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.49 in its last earnings report, missing expectations of -€0.18. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
MEDCL Stock 12 Month Forecast
Average Price Target
€36.60
▲(79.94% Upside)
Technical Analysis
Options Prices
Currently, No data available
---